publication venue for
- New Anti-thrombotic Agents: Emphasis on Hemorrhagic Complications and Their Management 2006
- Developing a novel antithrombotic in the academic environment 2001
- Looking forward in the treatment of deep-vein thrombosis 2001
- The clinical management of heparin-induced thrombocytopenia 1999
- Clinical presentation of heparin-induced thrombocytopenia 1998
- Limitations of conventional treatment options for heparin-induced thrombocytopenia 1998
- Comparison of the relative efficacy and safety of low molecular weight heparin and unfractionated heparin for the treatment of deep venous thrombosis 1997
- Epidemiology of VITT. 59:72-75. 2022
- Epidemiology of VITT.. 59:72-75. 2022
- Laboratory testing for VITT antibodies. 59:80-88. 2022
- Platelet-activating anti-PF4 disorders: An overview. 59:59-71. 2022
- Treatment of vaccine-induced immune thrombotic thrombocytopenia (VITT). 59:89-96. 2022
- Vaccine-induced immune thrombotic thrombocytopenia (VITT). 59:57-58. 2022
- Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia. 50:S18-S21. 2013
- A Rational Approach to the Diagnosis and Management of Thrombocytopenia in the Hospitalized Patient. 48:251-258. 2011
- Introduction: Practical Issues in Hemostasis and Thrombosis. 48:241-241. 2011
- Management of Bleeding Complications in the Anticoagulated Patient. 48:285-294. 2011
- Pregnancy-Associated Venous Thromboembolism: Prevention and Treatment. 48:271-284. 2011
- Hypercoagulability in Multiple Myeloma and Its Precursor State, Monoclonal Gammopathy of Undetermined Significance. 48:46-54. 2011
- Misconceptions, Challenges, Uncertainty, and Progress in Guideline Recommendations. 45:167-175. 2008
- On-Label Versus Off-Label Use of Recombinant Activated Factor VII: A Comprehensive Review of Use in Two Canadian Centers. 45:S68-S71. 2008
- Current Options for the Treatment of Idiopathic Thrombocytopenic Purpura. 44:S12-S23. 2007
- Pentasaccharides. 39:158-171. 2002
- Developing a novel antithrombotic in the academic environment. 38:4-11. 2001
- Looking forward in the treatment of deep-vein thrombosis. 38:49-57. 2001
- Idiopathic immune thrombocytopenic purpura: An update. 37:219-221. 2000
- Laparoscopic splenectomy in chronic idiopathic thrombocytopenic purpura. 37:267-274. 2000
- Management of idiopathic thrombocytopenic purpura in pregnancy. 37:275-289. 2000
- The use of electron microscopy in the investigation of the ultrastructural morphology of immune thrombocytopenic purpura platelets. 37:222-228. 2000
- The use of electron microscopy in the investigation of the ultrastructural morphology of immune thrombocytopenic purpura platelets. 37:222-228. 2000
- Thrombosis and anticoagulation. 36:118-132. 1999
- Thrombosis and anticoagulation.. 36:118-132. 1999
- The clinical management of heparin-induced thrombocytopenia.. 36:17-21. 1999
- Clinical presentation of heparin-induced thrombocytopenia.. 35:9-16. 1998
- Limitations of conventional treatment options for heparin-induced thrombocytopenia.. 35:17-25. 1998
- Comparison of the relative efficacy and safety of low molecular weight heparin and unfractionated heparin for the treatment of deep venous thrombosis.. 34:20-25. 1997
- Bleeding associated with antithrombotic therapy.. 17:259-291. 1980
- Hypercoagulability.. 14:409-425. 1977
- The haemolytic-uraemic syndrome.. 6:162-180. 1969